OBJECTIVE: To observe the improvement of functional dyspepsia (FD) after helicobacter pylori (HP) eradication in FD patients. METHODS:644 FD patients were recruited of whom 585 completed follow up. They were divided into postprandial distress syndrome (PDS) group and epigastric pain syndrome (EPS) group. Patients with HP infection were randomly allocated into eradication group and non-eradication group. Patients in the eradication group were randomly assigned into two groups and treated with triple therapy and sequential therapy, respectively. Patients in non-eradication group and HP non-infection group were treated with Domperidone (PDS patients) or Talcid (EPS patients). Clinical symptoms were evaluated. RESULTS: When compared with patients with unsuccessful HP eradication and without eradication, significant improvement in symptoms was found at 8 w, 12 w, and 26 w in patients with successful HP eradication in EPS group (P < 0.05). However, in PDS group, improvement in symptoms was comparable among patients expect at 26 w after successful HP eradication (P < 0.05). Therapeutic efficacy in patients without HP eradication was poorer than that in HP negative patients in EPS group (P < 0.05), while in PDS group, symptoms were relived at 26 w and 52 w (P < 0.05). CONCLUSIONS: HP is one of pathogenic factors of FD and HP eradication may benefit FD patients, regardless therapeutic regimes, especially in EPS patients.
RCT Entities:
OBJECTIVE: To observe the improvement of functional dyspepsia (FD) after helicobacter pylori (HP) eradication in FDpatients. METHODS: 644 FDpatients were recruited of whom 585 completed follow up. They were divided into postprandial distress syndrome (PDS) group and epigastric pain syndrome (EPS) group. Patients with HP infection were randomly allocated into eradication group and non-eradication group. Patients in the eradication group were randomly assigned into two groups and treated with triple therapy and sequential therapy, respectively. Patients in non-eradication group and HP non-infection group were treated with Domperidone (PDSpatients) or Talcid (EPSpatients). Clinical symptoms were evaluated. RESULTS: When compared with patients with unsuccessful HP eradication and without eradication, significant improvement in symptoms was found at 8 w, 12 w, and 26 w in patients with successful HP eradication in EPS group (P < 0.05). However, in PDS group, improvement in symptoms was comparable among patients expect at 26 w after successful HP eradication (P < 0.05). Therapeutic efficacy in patients without HP eradication was poorer than that in HP negative patients in EPS group (P < 0.05), while in PDS group, symptoms were relived at 26 w and 52 w (P < 0.05). CONCLUSIONS:HP is one of pathogenic factors of FD and HP eradication may benefit FDpatients, regardless therapeutic regimes, especially in EPSpatients.
Authors: K McColl; L Murray; E El-Omar; A Dickson; A El-Nujumi; A Wirz; A Kelman; C Penny; R Knill-Jones; T Hilditch Journal: N Engl J Med Date: 1998-12-24 Impact factor: 91.245
Authors: Christopher J Black; Peter A Paine; Anurag Agrawal; Imran Aziz; Maria P Eugenicos; Lesley A Houghton; Pali Hungin; Ross Overshott; Dipesh H Vasant; Sheryl Rudd; Richard C Winning; Maura Corsetti; Alexander C Ford Journal: Gut Date: 2022-07-07 Impact factor: 31.793
Authors: Lucas Wauters; Ram Dickman; Vasile Drug; Agata Mulak; Jordi Serra; Paul Enck; Jan Tack; Anna Accarino; Giovanni Barbara; Serhat Bor; Benoit Coffin; Maura Corsetti; Heiko De Schepper; Dan Dumitrascu; Adam Farmer; Guillaume Gourcerol; Goran Hauser; Trygve Hausken; George Karamanolis; Daniel Keszthelyi; Carolin Malagelada; Tomislav Milosavljevic; Jean Muris; Colm O'Morain; Athanassos Papathanasopoulos; Daniel Pohl; Diana Rumyantseva; Giovanni Sarnelli; Edoardo Savarino; Jolien Schol; Arkady Sheptulin; Annemieke Smet; Andreas Stengel; Olga Storonova; Martin Storr; Hans Törnblom; Tim Vanuytsel; Monica Velosa; Marek Waluga; Natalia Zarate; Frank Zerbib Journal: United European Gastroenterol J Date: 2021-04 Impact factor: 4.623